Ocrevus (ocrelizumab) - Efficacy Zvidzidzo

Ocrevus (ocrelizumab) mushonga webhayoloji unoshandiswa kurapa multiple sclerosis (MS) uye rheumatoid arthritis (RA). Mushonga uyu wakabvumidzwa neFDA muna 2017 kurapwa kweMS uye muna 2021 kurapwa kweRA.

Chiito cheOcrevus chinobva pakuvhara mapuroteni eCD20, aripo pamusoro pemamwe masero emuviri wemuviri, kusanganisira masero anoita basa rinokosha mukuvandudza MS neRA. Kuvharisa maprotein eCD20 kunogona kuderedza kuita kwe immune system uye kuderedza kuzvimba kunotungamira mukukuvadzwa kwematishu.

Zvidzidzo pamusoro pekushanda kweOcrevus mukurapa kweMS neRA zvave zvichiitwa kwemakore akati wandei. Imwe yezvidzidzo zvekutanga, iyo yakabudiswa muThe Lancet muna 2017, yakanzi "Kushanda uye kuchengetedzeka kweOcrevus muprimary progressive multiple sclerosis." Chidzidzo ichi chakaitwa pavarwere vanopfuura mazana manomwe vakagamuchira Ocrevus kana placebo kwemavhiki makumi mapfumbamwe nematanhatu. Zvigumisiro zvakaratidza kuti Ocrevus yakaderedza zvakanyanya kufambira mberi kweMS kana ichienzaniswa ne placebo.

Imwe ongororo yakabudiswa muThe New England Journal of Medicine muna 2017 yakaongorora kushanda kweOcrevus mukudzokorora-remitting multiple sclerosis (RRMS). Chidzidzo chacho chakaitwa kune vanopfuura 1300 varwere vakagamuchira Ocrevus kana mumwe mushonga wekurapa RRMS. Mhedzisiro yacho yakaratidza kuti Ocrevus yakaderedza zvakanyanya huwandu hwekudzokazve muvarwere zvichienzaniswa nemumwe mushonga.

Zvidzidzo pamusoro pekushanda kweOcrevus muRA zvakaitwa zvakare. Mumwe wavo, akaburitswa muThe Lancet muna 2019, akaongorora kushanda kweOcrevus mu seropositive RA, inova imwe yeakanyanya kuomarara.